# Andreas Goutopoulos

> Andreas Goutopoulos is a medicinal chemist turned founder who spent over a decade leading chemistry at EMD Serono before starting Actithera in 2021 to reengineer how radiation is delivered to tumors. His bet is that covalent chemistry - permanent molecular bonds borrowed from oral drug design - can make radioligands stick to cancer longer and leave healthy tissue alone. In July 2025 he closed an oversubscribed $75.5M Series A after pitching more than 250 venture funds, largely as a one-person company.

- **Role:** Founder and CEO at Actithera
- **Organizations:** Actithera, M Ventures, EMD Serono, Northeastern University Center for Drug Discovery
- **Nationality:** Greek-American
- **Education:** PhD, Medicinal/Pharmaceutical Chemistry (anandamide analogs and the endocannabinoid system, under Alexandros Makriyannis), University of Connecticut
- **Known for:** Founded Actithera and raised an oversubscribed $75.5M Series A, largely as a single-person company, Led medicinal chemistry and discovery at EMD Serono for over a decade, Track record of more than a dozen development candidates across multiple therapeutic areas

## Career timeline

- **1990s** — PhD research at the University of Connecticut on cannabinoid receptor ligands and anandamide analogs
- **1990s-2000s** — Work at the Center for Drug Discovery (Northeastern University) on medicinal chemistry
- **2000s-2010s** — Over a decade at EMD Serono (Merck KGaA), leading medicinal chemistry and discovery
- **2010s-2020s** — Entrepreneur-in-Residence at M Ventures, leading science for oncology small-molecule biotechs
- **2021** — Founded Actithera to bring medicinal-chemistry thinking to radioligand therapy
- **2025-07** — Closed an oversubscribed $75.5M Series A co-led by M Ventures, Hadean Ventures, Sofinnova Partners and 4BIO Capital

## Achievements

- Founded Actithera and raised an oversubscribed $75.5M Series A, largely as a single-person company
- Led medicinal chemistry and discovery at EMD Serono for over a decade
- Track record of more than a dozen development candidates across multiple therapeutic areas
- Built a three-pillar radioligand discovery platform centered on covalent targeting, tumor residence time and an isotope-agnostic philosophy
- 46 publications and citations from more than 1,800 researchers on ResearchGate

## Latest updates

- **2025-07** — Actithera closed an oversubscribed $75.5M Series A to advance its covalent, isotope-agnostic radioligand pipeline.

## Links

- Website: https://actithera.com
- LinkedIn: http://www.linkedin.com/in/andreas-goutopoulos-4017481a

---

Profile page: https://yespress.io/andreas-goutopoulos
Published by YesPress — https://yespress.io
Last updated: 2026-08-21